UPDATES: NCCN Guidelines® and NCCN Compendium®
NCCN Flash Update distributed 10 October 2013
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Penile Cancer. These NCCN Guidelines® are currently available as Version 1.2014.
- Primary Evaluation (PN-1)
- Imaging by “MRI or ultrasound” was removed.
- Management of Bulky/Unresectable Inguinal Lymph Nodes (PN-5)
- For positive “unilateral; mobile” nodes or “multiple or bilateral inguinal lymph nodes; mobile or fixed” confirmed by fine needle aspiration, “neoadjuvant chemotherapy” was added as a treatment option.
- Principles of Chemotherapy
- For second-line therapy, “irinotecan” was removed as a treatment option. (PN-C 1 of 2)
- “Radiosensitizing agents and combinations (For radiotherapy with concurrent chemotherapy)” was separated into “preferred” and “alternate options.” (PN-C 2 of 2)
- The preferred options are “cisplatin alone, or in combination with 5-FU” and the alternate options are “mitomycin C in combination with 5-FU” and “capecitabine.”
- The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)
For the complete updated versions of the NCCN Guidelines, NCCN Drugs & Biologics Compendium (NCCN Compendium®) , and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.
To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.
Free NCCN Guidelines apps for iPad and Android tablets are now available! Visit NCCN.org/apps